Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer
This is the video Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer that can be downloaded, played and edit with our RedcoolMedia movie maker MovieStudio video editor online and AudioStudio audio editor online
VIDEO DESCRIPTION:
Play, download and edit the video Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer.
Dr Arjun Balar speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about updated data from the KEYNOTE 57 trial.
KEYNOTE 57 is a Phase II trial of Pembrolizumab for patients with high-risk non-muscle invasive bladder cancer unresponsive to bacillus calmette-guérin.
They found that the CR was 40%, and 53% of these was lasting 9 months or longer, showing durability for pembrolizumab.
The adverse events were manageable, and the KEYNOTE 676 will test a combination of pembrolizumab with BCG.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
Free download, play and edit video and audio from Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer using RedcoolMedia.net web apps